{"entity":{"id":"nct04724980","kind":"trial","name":"Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis","aka":[],"tldr":"A phase 1/2 trial of PRGN-2012 - Phase I; Dose Level 1 in rare cancers of childhood, run by Precigen, Inc, active and no longer recruiting.","summary":"Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis is a phase 1/2 interventional study registered as NCT04724980 by Precigen, Inc, with 38 participants enrolled, started 2021-03-16 and due to reach its primary completion in 2024-06-05. Interventions recorded: PRGN-2012 - Phase I; Dose Level 1, PRGN-2012 - Phase I; Dose Level 2 and PRGN-2012 - Phase II; Dose Level 2.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04724980","url":"https://clinicaltrials.gov/study/NCT04724980"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rare-childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04724980","phase":"1/2","setting":"A Phase 1/2 Study of Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis","sponsor":"Precigen, Inc","enrolled":38,"outcomes":[]},"route":"/trials/nct04724980/","neighbours":{"cancer":[{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/"}]}}